CD95（FAS/APO-1）抗原是急性淋巴细胞白血病患者原始细胞的一种新的预后标志物。

CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients.

作者信息

Polosukhina E R, Tupitsin N N, Gavrikova N V, Zabotina T N, Mayakova S A, Kurmashov V I, Syrkin A B, Kadagidze Z G

机构信息

Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia.

出版信息

Adv Exp Med Biol. 1999;457:251-8. doi: 10.1007/978-1-4615-4811-9_27.

DOI:10.1007/978-1-4615-4811-9_27

PMID:10500800

Abstract

We analyzed CD95(Fas/APO-1) antigen expression on bone marrow blasts in 38 children with acute lymphoblastic leukemia (ALL) receiving a treatment in the Department of Leukaemias at the Cancer Research Center in 1987-1989 years (n = 22) and in 1994-1997 years (n = 16). CD95 antigen expression was studied by monoclonal antibodies (MoAbs) IPO-4 in indirect immunofluorescence analysis. CD95 antigen was expressed on 35.8 +/- 7.5% bone marrow blasts, most frequently (63.6%) in the clinically favourable Pre-B ALL. Only in this group CD95 antigen expression was correlated with CD10 antigen expression that has a positive influence to the time of complete remission in ALL patients. Our data showed that CD95 expression on blast cells is a favourable prognostic sign, associated with increased relapse-free and total survival. On the contrary, the absence of CD95 antigen on blasts is an unfavourable sign for disease evolution.

摘要

我们分析了1987 - 1989年（n = 22）以及1994 - 1997年（n = 16）在癌症研究中心白血病科接受治疗的38例急性淋巴细胞白血病（ALL）患儿骨髓原始细胞上CD95（Fas/APO - 1）抗原的表达情况。通过间接免疫荧光分析，使用单克隆抗体（MoAbs）IPO - 4研究CD95抗原的表达。CD95抗原在35.8 +/- 7.5%的骨髓原始细胞上表达，在临床预后良好的前B - ALL中最为常见（63.6%）。仅在该组中，CD95抗原表达与CD10抗原表达相关，而CD10抗原表达对ALL患者的完全缓解时间有积极影响。我们的数据表明，原始细胞上的CD95表达是一个良好的预后指标，与无复发生存期和总生存期的延长相关。相反，原始细胞上缺乏CD95抗原是疾病进展的不良指标。